- Home
- NHIC vs CRVS Comparison
NHIC vs CRVS Comparison
Compare NHIC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHIC
- CRVS
- Stock Information
- Founded
- NHIC 2024
- CRVS 2014
- Country
- NHIC United States
- CRVS United States
- Employees
- NHIC N/A
- CRVS N/A
- Industry
- NHIC
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- NHIC
- CRVS Health Care
- Exchange
- NHIC NYSE
- CRVS Nasdaq
- Market Cap
- NHIC 276.7M
- CRVS 301.5M
- IPO Year
- NHIC 2025
- CRVS 2016
- Fundamental
- Price
- NHIC $10.21
- CRVS $3.92
- Analyst Decision
- NHIC
- CRVS Strong Buy
- Analyst Count
- NHIC 0
- CRVS 4
- Target Price
- NHIC N/A
- CRVS $15.00
- AVG Volume (30 Days)
- NHIC 312.0
- CRVS 786.0K
- Earning Date
- NHIC 01-01-0001
- CRVS 08-05-2025
- Dividend Yield
- NHIC N/A
- CRVS N/A
- EPS Growth
- NHIC N/A
- CRVS N/A
- EPS
- NHIC N/A
- CRVS N/A
- Revenue
- NHIC N/A
- CRVS N/A
- Revenue This Year
- NHIC N/A
- CRVS N/A
- Revenue Next Year
- NHIC N/A
- CRVS N/A
- P/E Ratio
- NHIC N/A
- CRVS N/A
- Revenue Growth
- NHIC N/A
- CRVS N/A
- 52 Week Low
- NHIC $10.02
- CRVS $1.75
- 52 Week High
- NHIC $10.55
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- NHIC N/A
- CRVS 49.54
- Support Level
- NHIC N/A
- CRVS $3.83
- Resistance Level
- NHIC N/A
- CRVS $4.33
- Average True Range (ATR)
- NHIC 0.00
- CRVS 0.28
- MACD
- NHIC 0.00
- CRVS -0.03
- Stochastic Oscillator
- NHIC 0.00
- CRVS 21.74
About NHIC NEWHOLD INVESTMENT CORP III
NewHold Investment Corp III is a blank check company.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).